Lord, Abbett & Co
NRIX icon

Lord, Abbett & Co’s Nurix Therapeutics NRIX Stock Holding History

Lord, Abbett & Co’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-437,772
Closed -$8.25M – 569
2024
Q4 		$8.25M Buy
437,772
+87,132
+25% +$2M 0.03% 406
2024
Q3 		$7.88M Buy
+350,640
New +$7.94M 0.03% 427

Other funds holding NRIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lord, Abbett & Co's NRIX Position: Q1 2025 in Review

Lord, Abbett & Co sold out of Nurix Therapeutics (NRIX) in Q1 2025, closing a stake of 437,772 shares — an estimated $8.25M sold.

Lord, Abbett & Co first reported a position in NRIX in Q3 2024 and held it in 2 quarters. The position peaked at $8.25M in Q4 2024. 170 funds tracked by Wall St. Rank hold NRIX as of Q1 2025.

  • Lord, Abbett & Co reported no remaining Nurix Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Lord, Abbett & Co sold 437,772 Nurix Therapeutics shares in Q1 2025, an estimated $8.25M.
  • Lord, Abbett & Co first reported a position in Nurix Therapeutics in Q3 2024 and held it in 2 quarters.
  • Lord, Abbett & Co's Nurix Therapeutics position peaked at $8.25M in Q4 2024.
  • 170 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2025.

Based on Lord, Abbett & Co's 13F filing for Q1 2025, filed 13 May 2025.